Magungunan kwayoyin halitta , waɗanda aka sayar da su ga wasu nau'in cututtukan cututtukan jini daga 1998, ana gudanar da su ko ta hanyar jiko ko yin allura . Sakamakon lalacewar, wanda zai iya faruwa tare da waɗannan kwayoyi, an kira su halayen jiko ko halayen halayen shafin. Sauti ban tsoro, ba haka ba? Amma, ya kamata ka san cewa halayen suna da wuya sosai kuma sau da yawa sun wuce ba tare da wani shiga ba.
Hanyoyin Kasuwanci na Gida
Shirye-shiryen da aka saba da nau'in halayen jiko zasu iya hada da ciwon kai, tashin zuciya, urticaria (hives), pruritus (itching), rash, flushing, zazzabi, juyayi, tachycardia (m zuciya), da dyspnea (wahalar numfashi).
Yayinda yake da wuya, halayya mai tsanani ko halayen anaphylactic zai iya faruwa. A irin waɗannan lokuta, ƙarar kirji, bronchospasm, hypotension (ƙananan jini), diaphoresis (sweating), ko anaphylaxis (wani rashin lafiyar mai tsanani da zai iya haifar da furotin da ke fitowa daga baya zuwa ga shi) na iya faruwa. Idan mummunan hali ya tasowa, ya kamata a dakatar da maganin lafiyar nan da nan kuma ana ba da taimakon gaggawa. A wasu lokuta, maganin rigakafi tare da acetaminophen, antihistamine, da kuma corticosteroid na gajeren lokaci na iya taimaka wajen hana jigilar haɗuwa.
Bisa ga masana marubuta na Rheumatoid Arthritis: Binciken Bincike da Kulawa da Farko , gwajin gwajin gwaji ya nuna cewa yayin da kimanin kashi 20 cikin marasa lafiya da aka yi tare da Remicade (infliximab) suna da nauyin jikowa, kasa da kashi 1 cikin dari na marasa lafiya da suka kamu da cutar sun ji rauni sosai. kawai 2.5% na halayen jikowa tsakanin marasa lafiya wanda aka kula da marasa lafiya ya haifar da dakatar da miyagun ƙwayoyi.
Yawancin lokaci, halayen jigilar haɗin da ke hade da Remicade ya faru a lokacin jiko ko cikin sa'o'i biyu bayan an kammala jiko.
Bari muyi la'akari da abin da ke bayani game da wasu kwayoyin halittu da aka bayyana, tunatar da cewa wasu gwaje-gwajen gwaje-gwaje ba za a iya kwatanta su ba (misali, sakamakon gwaji na Remicade ba za a kwatanta da sakamakon gwajin Simponi) kuma bayanan gwaji na iya ba daidai ba ne ga ainihin mita a ainihi aiki.
- Simponi Aria: A lokacin sarrafawa na gwajin 1 (ta mako 24), 1.1% na infosions Simponi Aria an hade da wani jigilar jigilar jiki idan aka kwatanta da 0.2% na infusions a cikin ƙungiyar kulawa. Rash shi ne mafi yawan jimlar jiko. Babu wani halayen jigilar jigilar jini.
- Orencia (abatacept): Orencia yayi nazari na III, IV, da V sun nuna cewa halayen jiko mai zurfi sun kasance mafi yawanci a cikin marasa lafiya marasa lafiya Orencia idan aka kwatanta da placebo (9% vs 6% daidai). Mafi yawan lokutta da aka ba da rahoto sun kasance rashin tsoro, ciwon kai, da kuma jigilar zuciya (1-2%). Kasa da kashi 1 cikin dari na marasa lafiya na Orencia sun dakatar da yin amfani da miyagun ƙwayoyi saboda mummunan jiko. Anaphylaxis ya faru a ƙasa da 0.1% na marasa lafiya da aka bi da Orencia.
- Actemra (tocilizumb): A cikin nazarin asibitocin da ake gudanarwa a cikin makonni 24, mummunar jigilar jini ya faru a 7-8% na marasa lafiya, dangane da wanda aka saba amfani da su na Actemra, idan aka kwatanta da kashi 5 a cikin rukuni na placebo. Mafi yawan abin da ya faru a lokacin jiko shine hauhawar jini (1%). Mafi yawan abubuwan da suka faru a cikin sa'o'i 24 na jiko sun kasance ciwon kai (1%) da halayen fata (1%). Abubuwan da suka faru bai haifar da katsewa ko iyakancewar jiyya ba.
- Rituxan (rituximab): Gudanarwa na Rituxan zai iya haifar da mummunan hali, ciki har da halayen jigilar jini. Mutuwa a cikin sa'o'i 24 na Rituxan jiko sun faru. Kimanin kashi 80% na halayen jigilar jigilar jini ya faru a cikin haɗuwa da farkon jiko.
A cikin Rituxan RA ko watsi da nazarin karatu na placebo, ƙananan jigilar haɗari (zazzabi, juyayi, rigors, pruritus, urticaria ko rash, angioedema, sneezing, makogwaro fushi, tari, ko bronchospasm, tare da ko ba tare da jigilar jini ko hauhawar jini ba) % na marasa lafiya na Rituxan wadanda suka biyo baya bayan jigilar su na farko, idan aka kwatanta da kashi 19% na rukuni na placebo. Halin da ake ciki na jigilar jigilar jigilar jigilar bayanan ta biyu na Rituxan ko placebo ya karu zuwa kashi 9% da 11%, daidai da haka. Maganin mummunan jigilar jigilar jigilar jigilar kwayoyin halitta sun sami goge bayan <1% na marasa lafiya a kowane bangare na jiyya.
An bukaci gyare-gyaren a cikin kashi 10 cikin dari na marasa lafiya na Rituxan da kashi 2% na ƙungiyar placebo.
Hanyoyin Kayan Kayan Wuta
Tare da kwayoyin kwayoyin da ake gudanarwa a ƙarƙashin hanya, halayen shafin yanar gizon zai iya faruwa amma yawanci babu buƙatar da ake buƙata kuma katsewa daga miyagun ƙwayoyi ba lallai ba ne.
Masu bincike kuma sun kalli bayanan jarrabawar gwaji don tantance yawan nauyin halayen injection. Yayin da yake bayar da wani ra'ayi, tuna, bambance-bambance daban-daban ba za a iya kwatanta su ba kuma bayanan jarrabawar ba dole ba ne na nuna abin da ke faruwa a cikin ainihin aikin.
- Enbrel (kwakwalwa): A cikin gwajin gwaji don yanayin rheumatologic, kimanin kashi 37 cikin dari na marasa lafiya da aka bi da su tare da Enbrel ci gaba da halayen halayen injection. Dukkanin halayen da ake yi da allurar sunadaran sun kasance mai laushi zuwa matsakaici (erythema, itching, zafi, kumburi, zub da jini, raguwar jiki) kuma ba a kai ga maganin miyagun ƙwayoyi ba. Hanyoyin haɓalin injection, mafi yawancin kwanaki 3 zuwa 5, yakan faru a farkon watanni kuma baya rage a mita.
- Humira (adalimumab): A cikin gwajin gwaji, kashi 20 cikin dari na marasa lafiya da aka bi da Humira sunyi haɓakawa a shafin yanar gizo (erythema, itching, hemorrhage, zafi ko kumburi), idan aka kwatanta da kashi 14 cikin dari na marasa lafiya suna samun wuribo. Yawancin halayen jigilar magungunan da aka kwatanta su ne m kuma ba lallai ba ne ya sa aka dakatar da miyagun ƙwayoyi.
- Simponi (golimumab): A cikin gwaji na Phase II / III, 3.4% na marasa lafiya Simponi sunyi halayen shafin yanar gizo idan aka kwatanta da 1.5% a cikin rukuni. Yawancin halayen da aka yi da inuwa sun kasance mai laushi da matsakaici, tare da mafi yawan bayyanar da ake ciki shine erythema.
- Cimzia (certolizumab pegol): An ambaci yiwuwar maganin injection tare da Cimzia a cikin bayanin da aka tsara, wanda aka bayyana a matsayin rare, amma babu cikakkun bayanai da aka bayar.
Sources:
Arthritis Rheumatoid: Farko da Sanin Sanarwar. Cush, Weinblatt, Kavanaugh. 2010. Batu na Uku. Kasuwanci Sadarwa, Inc.